Search

Search Results

• 

  Efficacy and safety of second-line agents for treatment of metastatic castration-resistant prostate cancer progressing after docetaxel. A systematic review and meta-analysis

  Gianpaolo Perletti, Elena Monti, Emanuela Marras, Anne Cleves, Vittorio Magri, Alberto Trinchieri, Paul S. Rennie

  121-129

  2015-07-07

  Published: July 7, 2015

  10571

  PDF: 4480

  SUPPLEMENTARY MATERIAL: 1004
• 

  Prostate-specific antigen response after Abiraterone treatment in mCRPC: PSA as a predictor of overall survival

  Alexandre Mendonça Macedo, Rita Gameiro Marques, Margarida Cunha André, Nuno Silva Figueira, Miguel Leal Carvalho

  2023-02-22

  Published: February 22, 2023

  1006

  PDF: 595
• 

  C reactive protein/Albumin ratio as predictor of prognosis in castration resistant metastatic prostate cancer

  João Lorigo, Edgar Tavares Silva, João Pedroso Lima, Vasco Quaresma, Rui Pedrosa, Arnaldo Figueiredo

  2023-07-11

  Published: July 11, 2023

  885

  PDF: 376
• 

  Novel hormonal agents for metastatic Castration-Resistant Prostate Cancer: comparing outcomes. A single-center retrospective study

  Roberto Saldanha Jarimba, Miguel Nobre Eliseu, João Pedroso Lima, Vasco Quaresma, Pedro Moreira, Pedro Coelho Nunes, Edgar Tavares da Silva, Arnaldo José Figueiredo

  393-398

  2021-12-20

  Published: December 20, 2021

  1537

  PDF: 621
• 

  Bone pain palliation outcomes and possibility of Radium-223 re-treatment in mCRPC

  Viviana Frantellizzi, Julia Lazri, Mariano Pontico, Arianna Pani, Giuseppe De Vincentis

  2020-10-01

  Published: October 1, 2020

  924

  PDF: 588